Louise K Francois Watkins1,2, Jennifer L Milucky1, Lesley McGee1, Florence Siné St-Surin3, Pengbo Liu1,4, Theresa Tran1, Sopio Chochua1, Gerard Joseph5, Nong Shang1, Stanley Juin6, Patrick Dely7, Roopal Patel6,8, Chris A Van Beneden1,9. 1. Respiratory Diseases Branch, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 3. Hôpital Universitaire de la Paix, Port-au-Prince, Haiti. 4. Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. 5. Laboratoire National de Santé Publique, Port-au-Prince, Haiti. 6. Centers for Disease Control and Prevention, Port-au-Prince, Haiti. 7. Ministère de la Santé Publique et de la Population, Directorate of Epidemiology, Laboratory and Research, Port-au-Prince, Haiti. 8. Global Fund to Fight AIDS, Tuberculosis, and Malaria, Grand-Saconnex, Switzerland. 9. Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Abstract
BACKGROUND: Streptococcus pneumoniae, or pneumococcus, is a leading cause of morbidity and mortality in children worldwide. Pneumococcal conjugate vaccines (PCV) reduce carriage in the nasopharynx, preventing disease. We conducted a pneumococcal carriage study to estimate the prevalence of pneumococcal colonization, identify risk factors for colonization, and describe antimicrobial susceptibility patterns among pneumococci colonizing young children in Port-au-Prince, Haiti, before introduction of 13-valent PCV (PCV13). METHODS: We conducted a cross-sectional study of children aged 6-24 months at an immunization clinic in Port-au-Prince between September 2015 and January 2016. Consenting parents were interviewed about factors associated with pneumococcal carriage; nasopharyngeal swabs were collected from each child and cultured for pneumococcus after broth enrichment. Pneumococcal isolates were serotyped and underwent antimicrobial susceptibility testing. We compared frequency of demographic, clinical, and environmental factors among pneumococcus-colonized children (carriers) to those who were not colonized (noncarriers) using unadjusted bivariate analysis and multivariate logistic regression. RESULTS: Pneumococcus was isolated from 308 of the 685 (45.0%) children enrolled. Overall, 157 isolates (50.8%) were PCV13 vaccine-type serotypes; most common were 6A (13.3%), 19F (12.6%), 6B (9.7%), and 23F (6.1%). Vaccine-type isolates were significantly more likely to be nonsusceptible to ≥1 antimicrobial (63.1% vs 45.4%, P = .002). On bivariate analysis, carriers were significantly more likely than noncarriers to live in a household without electricity or running water, to share a bedroom with ≥3 people, to have a mother or father who did not complete secondary education, and to have respiratory symptoms in the 24 hours before enrollment (P < .05 for all comparisons). On multivariable analysis, completion of the pentavalent vaccination series (targeting diphtheria, pertussis, tetanus, hepatitis B, and Haemophilus influenzae type b) remained significantly more common among noncarriers. CONCLUSIONS: Nearly a quarter of healthy children surveyed in Haiti were colonized with vaccine-type pneumococcal serotypes. This baseline carriage study will enable estimation of vaccine impact following nationwide introduction of PCV13. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
BACKGROUND: Streptococcus pneumoniae, or pneumococcus, is a leading cause of morbidity and mortality in children worldwide. Pneumococcal conjugate vaccines (PCV) reduce carriage in the nasopharynx, preventing disease. We conducted a pneumococcal carriage study to estimate the prevalence of pneumococcal colonization, identify risk factors for colonization, and describe antimicrobial susceptibility patterns among pneumococci colonizing young children in Port-au-Prince, Haiti, before introduction of 13-valent PCV (PCV13). METHODS: We conducted a cross-sectional study of children aged 6-24 months at an immunization clinic in Port-au-Prince between September 2015 and January 2016. Consenting parents were interviewed about factors associated with pneumococcal carriage; nasopharyngeal swabs were collected from each child and cultured for pneumococcus after broth enrichment. Pneumococcal isolates were serotyped and underwent antimicrobial susceptibility testing. We compared frequency of demographic, clinical, and environmental factors among pneumococcus-colonized children (carriers) to those who were not colonized (noncarriers) using unadjusted bivariate analysis and multivariate logistic regression. RESULTS: Pneumococcus was isolated from 308 of the 685 (45.0%) children enrolled. Overall, 157 isolates (50.8%) were PCV13 vaccine-type serotypes; most common were 6A (13.3%), 19F (12.6%), 6B (9.7%), and 23F (6.1%). Vaccine-type isolates were significantly more likely to be nonsusceptible to ≥1 antimicrobial (63.1% vs 45.4%, P = .002). On bivariate analysis, carriers were significantly more likely than noncarriers to live in a household without electricity or running water, to share a bedroom with ≥3 people, to have a mother or father who did not complete secondary education, and to have respiratory symptoms in the 24 hours before enrollment (P < .05 for all comparisons). On multivariable analysis, completion of the pentavalent vaccination series (targeting diphtheria, pertussis, tetanus, hepatitis B, and Haemophilus influenzae type b) remained significantly more common among noncarriers. CONCLUSIONS: Nearly a quarter of healthy children surveyed in Haiti were colonized with vaccine-type pneumococcal serotypes. This baseline carriage study will enable estimation of vaccine impact following nationwide introduction of PCV13. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
Authors: María E Toledo; Maria F Casanova; Nivaldo Linares-Pérez; Dagmar García-Rivera; Gilda Toraño Peraza; Indira Barcos Pina; Martha Montes de Oca; Laura M Rodriguez-Noda; Mayelín Mirabal; Beatriz Paredes; Dunia M Chávez Amaro; Darielys Santana Mederos; Yury Valdés-Balbín; Vicente Verez-Bencomo Journal: Pediatr Infect Dis J Date: 2017-01 Impact factor: 2.129
Authors: Ana Serrão Neto; Paula Lavado; Pedro Flores; Ricardo Dias; Maria Ana Pessanha; Eduarda Sousa; José Martins Palminha; Manuela Caniça; Julieta Esperança-Pina Journal: Microb Drug Resist Date: 2003 Impact factor: 3.431
Authors: Yin-Bun Cheung; Syed M A Zaman; Ekpedeme David Nsekpong; Chris A Van Beneden; Richard A Adegbola; Brian Greenwood; Felicity T Cutts Journal: Pediatr Infect Dis J Date: 2009-11 Impact factor: 2.129
Authors: Caroline C Tigoi; Hellen Gatakaa; Angela Karani; Daisy Mugo; Stella Kungu; Eva Wanjiru; Jane Jomo; Robert Musyimi; John Ojal; Nina E Glass; Osman Abdullahi; J Anthony G Scott Journal: Clin Infect Dis Date: 2012-04-20 Impact factor: 9.079
Authors: Aderonke Odutola; Martin Antonio; Olumuyiwa Owolabi; Abdoulie Bojang; Ebenezer Foster-Nyarko; Simon Donkor; Ifedayo Adetifa; Sylvia Taylor; Christian Bottomley; Brian Greenwood; Martin Ota Journal: PLoS One Date: 2013-09-23 Impact factor: 3.240